Revumenib (SNDX-5613) + venetoclax + decitabine and cedazuridine

May 12, 2026 — Syndax Pharmaceuticals (Nasdaq: SNDX) announced that 12 abstracts on Revuforj® (revumenib), its FDA-approved oral menin inhibitor, were released on the European Hematology Association (EHA) website ahead of the EHA 2026 Congress (June 11–14, 2026; Stockholm).

The abstracts cover revumenib activity across acute leukemia subtypes including KMT2A-rearranged (KMT2Ar), NPM1-mutated (NPM1m), and NUP98-rearranged (NUP98r) disease, spanning frontline, relapsed/refractory (R/R), real-world use, and post–hematopoietic stem cell transplant (HSCT) settings. Syndax highlighted: interim real-world ROAR study findings in R/R acute leukemia; updated Phase 1 frontline combination data with intensive chemotherapy; post-HSCT maintenance outcomes and a post hoc AUGMENT-101 post-transplant analysis; updated SAVE trial results combining revumenib with venetoclax and decitabine/cedazuridine; and activity in R/R NUP98r acute leukemia (AUGMENT-101 and expanded access).

Business/clinical significance: Syndax positions the EHA dataset as supporting broader use of revumenib (including combination and maintenance strategies) and informing ongoing pivotal trials (including Phase 3 REVEAL-ND NPM1 and other trials in progress).